In this edition:
Impact of lymph node burden and distribution on treatment response in mHSPC
Renal cancer evolution
Pembrolizumab + chemoradiotherapy for MIBC
High-dose testosterone + carboplatin in men with mCRPC
Impact of concomitant medications and comorbidities on NHAs in mCRPC
Water irrigation post TURBT for preventing recurrence of NMIBC
PARP inhibitor combination therapies in prostate cancer
Molecular characterisation of metastatic neuroendocrine prostate cancer
Determinants of anti-PD-1 response in ccRCC
PARP inhibitor + androgen receptor antagonist in mCRPC
Please login below to download this issue (PDF)